Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Free Cash Flow (2023 - 2025)

Immunocore Holdings' Free Cash Flow history spans 3 years, with the latest figure at -$35.5 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 102.65% year-over-year to -$35.5 million; the TTM value through Dec 2025 reached -$15.1 million, down 172.06%, while the annual FY2025 figure was -$15.1 million, 172.06% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$35.5 million at Immunocore Holdings, down from -$5.2 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $25.5 million in Q2 2025 and bottomed at -$35.5 million in Q4 2025.
  • The 3-year median for Free Cash Flow is -$606500.0 (2023), against an average of $279250.0.
  • The largest YoY upside for Free Cash Flow was 1814.15% in 2024 against a maximum downside of 166.56% in 2024.
  • A 3-year view of Free Cash Flow shows it stood at -$18.6 million in 2023, then rose by 5.47% to -$17.5 million in 2024, then plummeted by 102.65% to -$35.5 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Free Cash Flow are -$35.5 million (Q4 2025), -$5.2 million (Q3 2025), and $25.5 million (Q2 2025).